You track competitor pipelines, approvals, and safety — and leadership needs answers, sourced, on short turnaround. ClinicaLister links every trial to its approvals and safety profile, flags each change within hours, and lets your AI assistant turn it all into a board-ready brief with the source behind every number. IP timelines are the gap: see the limitations below before promising a patent-cliff view.
The highest-leverage things ClinicaLister does for a competitive intelligence analyst.
Every recurring activity, mapped to what ClinicaLister does — on which surface (the App, the MCP graph, or both), the time it saves, and how confident that claim is.
| Activity | What ClinicaLister does | Surface | Time saved | Confidence |
|---|---|---|---|---|
| Cross-ref a drug vs Drugs@FDA / EPAR | Every drug arrives already linked to its FDA and EMA approvals and label, each link confidence-scored and traceable to its source. Orange Book patent data is not part of this — see limitations. | Both | multi-DB merge → seconds | High |
| Look up patent / exclusivity dates on a specific drug | Where the FDA record carries them, patent and exclusivity end-dates are returned with the drug. Coverage is 4.4% and 1.8% respectively, so this answers a per-drug question and cannot produce a portfolio cliff timeline. | Both | per-drug lookup only | Low |
| Watch several competitors at once | A single saved watchlist matches many sponsors at once and auto-follows their new trials as they appear, so you maintain one query instead of one per rival. | Both | one multi-sponsor watchlist, not a query each | High |
| New-entrant early-warning sweep | A recent-window scan surfaces newly registered trials from your watched sponsors in a single pass, replacing the weekly manual trawl. | Both | weekly trawl → one call | High |
| Detect protocol / status changes on watched trials | Field-by-field change detection flags status flips, endpoint edits, and sponsor transfers on every watched trial, with a severity-ranked diff of exactly what moved. | Both | amendments in hours | High |
| Comparative safety across molecules | Side-by-side adverse-event and disproportionality analysis compares safety across competing molecules straight from FDA reporting data. | Both | ad-hoc pulls → side-by-side | High |
| Drug-shortage awareness | FDA shortage status sits on every portfolio drug, turning a competitor's supply gap into a market-share signal without manual checks. | Both | manual FDA checks removed | High |
| Competitive density / landscape for an indication | A generated pipeline matrix maps the sponsors and phases active in an indication, replacing days of hand-built grids. | Both | days of hand-built grids → generated | High |
| Single-competitor portfolio rollup | Your AI assistant compiles one competitor's entire tracked portfolio into a single sourced rollup report. | MCP | full picture in one report | High |
| Biosimilar presence on a reference drug | Where the FDA record carries Purple Book data (3.07% of drugs), biosimilar and interchangeability status is shown. It is a per-drug lookup, not a tracked pipeline, and it carries no loss-of-exclusivity timing. | App | per-drug lookup only | Low |
| Investigator / site overlap | Your AI assistant cross-tabs the investigators and sites shared across competing trials into a single overlap map. | MCP | auto cross-tab of PIs | Medium |
| Sponsor moves / momentum | Sponsor change activity and trial-start momentum reveal directional shifts in a competitor's program without any manual diffing. | Both | directional shifts, no manual diff | Medium |
| US vs EU footprint | EU and US registry records are linked per asset, reconciling a competitor's global trial footprint across both systems. | Both | CTIS↔CT.gov reconcile removed | Medium |
| Market size behind an asset | US spend and pricing signals — Medicare Part D, ASP, and NADAC — give rough market sizing behind an asset without wrangling CMS files. | MCP | rough sizing without CMS files | Low |
| Board / leadership deck assembly | Confidence-scored links plus a one-click Excel export hand you presentation-ready, fully sourced data — you still build the slides. | App | presentation-ready data (not slides) | Medium |
Straight answers on where ClinicaLister stops today — so there are no surprises.
Purple Book / biosimilar coverage is 3.07% of drug records (915 of 29,777; only 48 carry a biosimilar mention) and exclusivity end-dates 1.8%, measured 2026-08-17. Biosimilar and interchangeability status is therefore a per-drug lookup that often comes back empty — it is not a tracked feed, and it cannot time loss-of-exclusivity.
Only what's public is visible. Coverage is limited to what registries and regulators disclose — pre-registration, stealth, and undisclosed in-licensing programs won't appear until they surface.
Suggested links are suggestions, not facts. AI-matched drug–trial links are confidence-scored, and the low-confidence ones still need an analyst's judgment before they reach a board.
No finished slide deck. Export gives you clean, sourced data; the analyst still writes the narrative and builds the presentation.
Not a war-gaming tool. It surfaces and sources the signals — threat scoring, positioning, and response strategy are yours.
Patent and exclusivity coverage is thin, and this is the honest number: of 29,777 FDA drug records we hold patents on 4.4%, exclusivity end-dates on 1.8%, and Purple Book patents on 0.05% (measured 2026-08-17). That supports a per-drug lookup where the data happens to exist — it does NOT support a portfolio patent-cliff or loss-of-exclusivity timeline, and we would rather say so than return an empty chart that reads as "nothing expiring". A full Orange Book / Purple Book feed is not yet ingested.
Structured fields have blind spots. Biologic patent cliffs and some device recalls live in sources your AI assistant has to reach for, so treat an empty field as a prompt to dig, not an all-clear.
Trials arrive already linked to their FDA and EMA approvals, comparative safety, and shortage signals, with every change flagged within hours and a source behind every claim — intelligence you can hand to the board without re-checking it.